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Abstract: Neuropathic pain (NP) is an enormous burden for patients, caregivers and society.
NP is a pain state that may develop after injury of the peripheral or central nervous system
because of a wide range of diseases and traumas. A NP symptom component can be found
also in several types of chronic pain. Many NP patients are substantially disabled for years.
Due to its chronicity, severity and unpredictability, NP is difﬁcult to treat. Tapentadol is
a central-acting oral analgesic with combined opioid and noradrenergic properties, which
make it potentially suitable for a wide range of pain conditions, particularly whenever a NP
component is present or cannot be excluded. In randomized controlled trials, tapentadol has
proved to be effective in relieving NP in diabetic peripheral neuropathy and in chronic low
back pain. In observational studies, tapentadol reduced NP in chemotherapy-induced periph-
eral neuropathies, blood and solid cancers, and the NP component in neck pain and
Parkinson’s disease. This narrative review aims to provide clinicians with a broad overview
of tapentadol effects on NP.
Keywords: neuropathic pain, tapentadol, pain therapy
Introduction
Neuropathic pain
Neuropathic pain (NP) has been deﬁned as a “pain arising as a direct consequence
of a lesion or disease affecting the somatosensory system”.1–4 NP results from
maladaptive neuroplastic responses that follow a “damage” to the nervous system
from a large range of potential causes (ie, peripheral neuropathies, spinal cord
injuries, and brain lesions). NP is characterized by spontaneous pain in the absence
of sensory stimuli and almost always by a variety of symptoms of sensory loss (ie,
hypoesthesia and hypoalgesia) and/or sensory gain (ie, tactile and mechanical
allodynia).1–4 As no gold standard exists, a grading system has been proposed
and revised to provide a level of diagnostic accuracy from unlikely NP to possible,
probable and to deﬁnite NP. This is based on the plausibility of the neuroanatomic
distribution of pain symptoms and sensory abnormalities, and on the demonstration
of their relationship with a nervous system lesion by diagnostic conﬁrmatory tests
(ie, neurophysiological testing and/or neuroimaging).1–4 History of NP and objec-
tive sensory disturbances are required for diagnosis of probable NP and
treatment.1–4
However, NP may not be an all-or-nothing event associated with speciﬁc
neurological conditions but rather a part of a spectrum of chronic pain where
pain can be “more or less neuropathic” in different clinical conditions.5,6 While it
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has been designed for patients undergoing diagnostic
assessment for characteristic neurological lesions (ie, dia-
betic painful neuropathy, and multiple sclerosis), the NP
grading algorithm may not work so well in disorders with
mixed pain, nociceptive pain and NP, which represent the
most commonly encountered pain conditions in clinical
practice (ie, cancer pain, low back pain, post-traumatic
and post-surgical pain).7,8 In these patients, it may be
difﬁcult or impossible to conﬁrm a neurological lesion
and reach diagnostic accuracy (ie, probable or deﬁnite
NP) required for NP treatment.7,8 NP grading has been
used more in research than in the clinical setting, and has
not yet been advocated by IASP.2,7,8 As a consequence,
a substantial number of patients with mixed pain may not
receive appropriate treatment for NP.7,8 In order to prevent
a signiﬁcant number of patients from not receiving an
appropriate treatment, revisions of IASP diagnostic criteria
for NP are being proposed.2,7,9
In clinical practice, as Bouhassira and Attal7 pointed
out, the pain features are diagnosed before the identiﬁca-
tion of the underpinning tissue and neural lesions, and may
guide treatment.7 NP patients report a small and consistent
group of sensory abnormalities (see above), which suggest
that, in spite of their different etiologies, NP conditions
may share common pathophysiological mechanisms.3,7
Based on patient NP descriptors and to circumvent prac-
tical difﬁculties of NP diagnostic grading in
a non-specialist environment, several questionnaires have
been developed and validated as NP screening and assess-
ment tools.3,7 The Neuropathic Pain Symptom Inventory
(NPSI) and painDetect questionnaire (PDQ) depend
entirely on patient self-report; and Signs scale in the
Leeds Assessment of Neuropathic Symptoms (LAANS)
and Douleur Neuropathique en 4 Questions (DN4) rely
on interview responses and on physical ﬁndings.3
Although less accurate than the NP grading system, NP
questionnaires have shown good sensitivity and speciﬁcity
in validation studies; cut-off values have been set to indi-
cate the probability of NP.3,7 NP questionnaires are being
used extensively to assess prevalence of NP at population
level and in chronic pain conditions.3,7
Chronic NP and chronic pain per se are both highly
disabling disorders. The prevalence of NP is estimated to
be between 7% and 10% in the general population and
many NP patients are signiﬁcantly disabled for years from
a moderate-to-severe pain.10,11 Worldwide, chronic pain
(ie, lasting longer than 3–6 months) affects at least 20%
of people and encompasses ﬁve of the eleven top, leading
conditions for years lived with disability.8,12 The preva-
lence of NP is up to 20–25% in patients reporting chronic
pain when mixed pain is included; a signiﬁcant NP com-
ponent is thought to contribute to the considerable loss of
quality of life (ie, altered cognition, mood, and sleep),
employment, and increased healthcare and social costs
caused by chronic pain.3–5,10–19
A high frequency of NP symptoms has been reported in
neurological and rheumatological disorders that are not typi-
cally associated with NP conditions (ie, without identiﬁable
neural correlates), such as motor neuron disease, Parkinson’s
disease, Alzheimer’s disease, low back pain, knee and hip
arthritis, and rheumatoid arthritis.3,5,20–32 In these condi-
tions, nociceptive pain and inﬂammatory pain are due to
activation of nociceptors from tissue damage and/or from
release of inﬂammatory mediators because of abnormal
postures, muscle rigidity, constipation, and/or joint tissue
inﬂammation.20–32 It not clear yet whether NP symptoms
are caused by chronic nociceptive pain itself via a peripheral
and/or central sensitization process, which may include acti-
vation threshold shift, upregulation of voltage-gated sodium
channels, N-methyl-D-aspartate-type glutamate receptor and
neuropeptide receptor activation, but no neural lesion.5
Alternatively, however, in rheumatological conditions NP
has been postulated to be due to somatosensory lesions,
such as loss of nerve terminals and/or ectopic innervation,
which have been described in articular and periarticular
tissues; much alike, in neurodegenerative disorders, changes
of the peripheral and central somatosensory system have
been pathologically identiﬁed and linked to NP.24–28 When
a neural lesion can be only hypothesized and not demon-
strated, the occurrence of NP symptoms has been variously
labeled as “NP component,” “NP mechanisms,” “NP-like
phenotype,” “pain with NP features,”, or “NP
symptoms.”8,27,33
However, whatever the cause, it is clinically relevant
that patients with a high probability of NP present with
higher comorbidity and with a poorer quality of life and
surgical outcome than their counterparts with a low level of
NP symptoms.24,27,28,33–35 Untreated NP may cause trials to
fail and, conversely, treating NP symptoms with antineuro-
pathic agents may be beneﬁcial to patients.3,5–21 The efﬁ-
cacy of currently available pharmacological and non-
pharmacological treatments for NP are limited with rando-
mized controlled trials (RCTs) reporting only a 30–48%
beneﬁt rate with active treatment compared with 11–30%
with placebo.21–25 The number of patients reporting
a clinically meaningful pain relief (ie, commonly at least
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50% decrease of pain intensity) with any treatment is low,
usually 10–25% more than with placebo. Preclinical and
clinical studies indicate that NP is associated with hyper-
excitabiliy of pain ascending pathways and to decreased
pain modulation by descending noradrenergic
pathways.15,19 For NP, recent guidelines place NRI antide-
pressants among ﬁrst-line drugs that may strengthen des-
cending inhibitory pain controls.15,19 Opioids act mostly by
inhibiting ascending pain pathways and are recommended
as second- or third-line treatments for NP.15,19 For nocicep-
tive pain, NSAIDs and acetominophen are the ﬁrst-line
treatments but they are often limited by lack of efﬁcacy
and potential life-threatening side effects, especially in older
patients.36 Opioids should be considered in all patients with
chronic moderate-to-severe nociceptive pain and with pain-
related impairment of functions and quality of life, and for
whom NSAIDs are contraindicated or ineffective.36
Therefore, a dual action, anti-neuropathic and -nociceptive
agent may be particularly advantageous in clinical condi-
tions with a mixed, nociceptive and neuropathic pain, which
is a common pain state in the clinical practice.8
Tapentadol
Tapentadol is a strong analgesic with a unique dual
mechanism of action that combines μ-opioid receptor
agonism (MOR) and norepinephrine reuptake inhibition
(NRI), and has been proposed to be the ﬁrst representative
of a new class of drugs, the MOR-NRI agents (µ-opioid
receptor agonists and norepinephrine reuptake
inhibitors).37–39 The MOR mechanism interrupts pre- and
post-synaptic transmissions of ascending pain signals in
the spinal cord and activates the descending inhibitory
projections supraspinally, while NRI increases synaptic
norepinephrine and enhances the descending inhibitory
tone (Figure 1).27,30,31 NRI drugs are known to be useful
in chronic NP.15,18,37,40 Interestingly, experimental and
clinical evidence indicates that the NRI component of
tapentadol may become predominant in NP
conditions.37,39–43 In addition, the NRI activity of tapenta-
dol has the potential to counteract the adverse MOR-
mediated effects on hippocampal neurogenesis, thus
resulting in less or no dysfunction in adult neurogenesis
and associated functions, such as memory.44 Finally,
tapentadol shows minimal serotoninergic activity, which
is important in the prolonged management of patients,
since serotoninergic pathways may promote pain and
nausea.39
Therefore, the use of tapentadol could expand the phar-
macological armamentarium against NP, which is often chal-
lenging to treat with other analgesics or co-analgesics, such as
Ascending pathway
to the brain
Pain signal
Descending pathway
from the brain
Spinal cord
Tapentadol
u-OR
NE
a2-AR
SP
Glu Primary afferent
Secondary
afferent
= Glutamate (Glu) = Substance P (SP)
= Substance P receptor
= Norepinephrine (NE) = NE reuptake transporter protein
= Mu-opioid receptor (u-OR)= Alpha2-adrenoreceptor= Glutamate receptor
Simplified schematic for mechanism of action
Figure 1 Schematic drawing of the dual mode action of tapentadol. Reproduced with permission from Chang EJ, Choi EJ, Kim KH. Tapentadol: can it kill two birds with one
stone without breaking windows? Korean J Pain. 2016 Jul;29(3):153–157.41
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antidepressants or anticonvulsants.45–50 In phase III studies,
tapentadol has been shown to be effective and well tolerated
for the management of moderate-to-severe chronic pain, of
either non-oncological and oncological origin.37,38,51–54
In spite of its therapeutic potential, there have been
only a few randomized control trials (RCTs) on tapenta-
dol’s antineuropathic activity. However, in observational
studies, the effects of tapentadol have been reported on
secondary outcome measures of NP associated with dif-
ferent clinical conditions. Patients were treated by hema-
tologists, neurologists, oncologists and pain specialists
over a 3–6-month period (see below). This is a narrative
review of existing evidences on the effects of tapentadol in
chronic NP (see Table 1 for an overview).
Search strategy and study selection
Our aim was to report evidence from the available litera-
ture of antineuropathic properties of tapentadol. We
searched for articles in EMBASE, MEDLINE and
PubMed, with the terms “tapentadol” and “neuropathic,”
“DN4,” “LANSS,” “PainDETECT,” “Neuropathic Pain
Symptom Inventory,” “McGill Short Form Pain
Questionnaire.” We only included human studies that
assessed the effects of tapentadol on NP measures. Some
relevant features of the studies (ie, author, clinical condi-
tion, methodology, patient numbers, pain and NP out-
comes) are reported in Table 1. All studies evaluated
tapentadol extended or prolonged release (PR).
Tapentadol in painful peripheral
neuropathies
Painful peripheral neuropathies (PPN) are a group of the
peripheral nervous system disorders with heterogeneous
etiologies (ie, genetic, inﬂammatory, metabolic, toxic and
traumatic).55 PPN are the most frequent NP conditions that
impair physical and mental functions and that may, even-
tually, affect quality and expectancy of life.1–4,55–67 While
the prevalence of postherpetic neuralgia (PHN) is expected
to decrease thanks to vaccination, diabetic peripheral neu-
ropathy (DPN) and chemotherapy-induced neuropathy
(CINP) are likely to increase because of the epidemics of
obesity and diabetes and because of improved survival of
cancer patients, respectively. In total, 25% of diabetics
develop DPN. Worldwide, the number of people with
diabetes has quadrupled in the last 30 years to
422 million people and a prevalence of 8.5%.64 CIPN is
the major dose-limiting adverse event by cancer
chemotherapy with platinum agents, taxanes, vinka alka-
loids, thalidomine and bortezomid; CINP pain may last
a long time and force treatment discontinuation, eventually
impacting on rehabilitation and survival.66,67
Both central and peripheral mechanisms are involved
in DPN, including polyol pathway hyperactivity, Na+-
channel proliferation in peripheral nerves, microvascular
nerve ischemia, altered Schwann cells, abnormal thalamic
activity and impaired descending inhibitory function in the
central nervous system.68–71 Studies on PHN and CINP
have focused on pathological changes in dorsal root gang-
lia and nerve endings. CINP pathophysiology has not been
fully elucidated. Taxanes may cause NP by disrupting
mitochondrial energy production and axoplasmic ﬂow.72
However, in contrast to initial reports of poor drug entry,
taxanes also enter the central nervous system and, that
way, may cause altered sensation and pain.66,67
Monotherapy with non-opioid or opioid analgesics pro-
vides insufﬁcient relief, and therefore combinations thera-
pies with different classes of drugs are tried.18,37,45,46,56,59
Although effective, opioid analgesics are considered
a second-line treatment in this setting due to their overall
poor tolerability and safety proﬁle including the potential
risk of abuse or misuse in the long run.46,56,73–75 In experi-
mental and clinical DPN, NRI antidepressants improve NP
by enhancing or restoring the noradrenergic descending
inhibitory pathways.19 The NRI mechanism of tapentadol
action appears to be dominant over the MOR activity in
chronic NP.37,39–43 Hence, because of its dual mechanisms
of action and in particular its NRI component, tapentadol
may be beneﬁcial to PPN.39–43
Postherpetic neuralgia
Tominaga et al reported a 12-week (ie, ≤6-week titration
plus maintenance periods), double-blind, placebo-
controlled RCT on 31 patients treated with tapentadol
extended release (ER) for PHN or DPN (mean dose
274.5±148.3 mg/day).58 The last observation carried for-
ward (LOCF) was used for imputing missing pain intensity
data for the primary endpoints, which were then analyzed
using the analysis of covariance (ANCOVA) on all patient
populations (intention to treat [ITT]). In a subset of 13
PHN patients, tapentadol PR was not superior to
placebo.58 Pain Numerical Rating Scale (NRS) declined
from pretreatment to treatment week 12 from 7.0±1.4 to
5.0±2.9 in the placebo group and from 6.7±0.9 to 4.5±2.3
in the tapentadol group (mean reduction 2.0±2.4 and 2.2
±2.2).58 No difference was observed between placebo and
Freo et al Dovepress
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treatment groups for the patient global impression of
change and for responders at ≥30% and ≥50% pain
reduction.58 These negative and disappointing ﬁndings
have been ascribed to study design factors such as study
underpower, heterogeneity of patients contributed in small
numbers by 33 study centers in Japan, potential genetic
factors and high numbers of uncontrolled concurrent med-
ications; the authors reported also an unusually high pla-
cebo response probably due to large expectations
generated in the patients from the 2:1 (treatment:placebo)
enrollment design.58 Recently, in the context of a complex
therapy including gabapentin 1800 mg/day, oxacarbaze-
pine 600 mg/day and amytriptiline 20 mg/day, tapentadol
500 mg/day failed to relieve pain in a 68-year-old patient
suffering from trigeminal PHN.76
Diabetic painful neuropathy
In the RCT on NP by Tominaga et al tapentadol PR failed
to outperform placebo in the subset of 18 DPN patients.58
From pretreatment to treatment end, pain NRS declined on
average by 2.9±2.43 in the placebo group and 2.8±2.24 in
the tapentadol PR group.48 The study on DPN was ﬂawed
like that on PHN.58
Schwartz et al conducted a phase III RCT to evaluate
safety and efﬁcacy of tapentadol PR in 588 DPN patients
poorly responsive (NRS ≥5) to previous treatments.57
Enrolled subjects were titrated to an optimal dose of tapenta-
dol PR (200/500 mg/day) over an open-label 3-week period.
Then, patients (n=395) with ≥1-point reduction in pain inten-
sity were randomly assigned to receive the identiﬁed opti-
mum dose of tapentadol or placebo for a 12-week double-
blind phase.57 The primary efﬁcacy outcome was the change
in average pain NRS. The mean change in average pain NRS
from the start of double-blind treatment to week 12was 1.4 in
the placebo group and 0.0 in the tapentadol PR group
(ANCOVA analysis on ITT and LOCF population).57
Overall, the mean difference between groups in the change
of average pain NRS from initiation of the double-blind
phase to week 12 was −1.3 (95% CI: −1.70 to −0.92,
P<0.001). In total, 61% (356/588) of patients reported
a ≥30% improvement in pain intensity during the open-
label phase; among patients randomized to tapentadol PR,
54% (105/196) reported a ≥30% improvement from the
initiation of the study to week 12. No new safety signals
were reported.57
These ﬁndings were corroborated by another RCT with
a very similar design.59 In this trial, a total of 358 patients
completed the titration period; of these, 166 were assigned
to tapentadol PR and 152 to placebo.59 Mean pain on a
0–10-point NRS was 7.33±1.30 at the start and 4.16±2.12
at week 3 of the open-label titration period; mean change
in average pain NRS from the start to week 12 of double-
blind treatment was 1.30±2.43 in the placebo group and
0.28±2.04 in the tapentadol PR (ANCOVA on ITT and
LOCF data). The mean difference in pain intensity from
the initiation of the double-blind treatment to week 12
between tapentadol PR and placebo was −0.95 (95% CI:
−1.42 to −0.49, P<0.001).59
In 2015, Schwartz et al performed a pooled analysis of
the two comparable, above-mentioned studies in DPN
patients.60 The reported median duration of exposure to
tapentadol PR during the double-blind maintenance period
was 84 days. The median daily dose of tapentadol PR was
400 mg during this period.50 Mean changes in pain intensity
from baseline to week 12 of maintenance in the placebo
(n=343) and tapentadol PR (n=360) group were 0.08±1.87
and 1.28±2.41, respectively, with a least squares mean
difference of −1.14 (95% CI: −1.43 to −0.84, P<0.001),
favoring tapentadol PR. Interestingly, this advantage of
tapentadol was observed across different patient subgroups
(ie, age, gender, ethnicity, opioid experience and pain inten-
sity), and was paralleled by improved quality of life.
Similarly, an advantage for tapentadol PR was observed in
terms of response rates.60 In conclusion, the pooled results
showed that tapentadol PR is effective in the management
of DPN-related pain, with consistently robust analgesic
efﬁcacy across different patient subgroups.
Niesters et al performed an interesting double-blind,
mechanistic RCT in 24 DPN patients who received either
placebo or tapentadol sustained release (SR) for 4 weeks.43
Patients were selected from a group of 81 patients if they
had at least two of the following symptoms in legs, arms
or both (in a stocking-glove distribution): 1) symmetrical
dysesthesias or paresthesias; 2) burning or painful feet
with night-time worsening; or 3) peripheral tactile allody-
nia; and 4) an abnormal warm or cold detection threshold,
an abnormal warm or cold pain threshold, or allodynia at
the Quantitative Sensory Test.43 Then, patients were
assessed before treatment and weekly up to week 4 of
treatment with a 0–10 pain Visual Analogue Scale (VAS)
and with two functional measures of pain modulatory
pathways, the conditioned pain modulation and the offset
analgesia.43 In comparison to placebo, tapentadol deter-
mined larger pain relief and larger conditioned pain
responses.43 From baseline to treatment week 4, pain
VAS declined from 6.5±0.6 to 4.8±0.7 in the placebo
Freo et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Journal of Pain Research 2019:121542
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
16
2.
24
1.
19
8 
on
 2
2-
M
ay
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
group and to 3.9±0.6 in the tapentadol SR group (ANOVA
and two-tailed t-test analyses; P=0.03); in the same time,
conditioned pain response increased from 9.1±5.4% to
14.3±7.2% with placebo treatment and to 24.2±7.7%
with tapentadol (P<0.001). In comparison to placebo,
tapentadol SR provided a larger correlated effect on pain
and conditioned pain modulation suggesting that tapenta-
dol SR improves NP by enhancing NRI pathways, that
project from brainstem to spinal cord.43
Diabetic pain may include peripheral artery disease
pain. In a study on 2,514 diabetics with pain in lower
limbs, 9% had DPN alone, 8.5% had peripheral artery
disease alone and 2.4% had both conditions which is
named lower-extremity disease.65 Peripheral artery dis-
ease can cause pain of mixed, nociceptive and neuro-
pathic origin.65 Therefore, analgesic treatment has to
overcome both nociceptive and NP components of the
pain. Given its dual mechanism of action, tapentadol may
be considered suitable for this condition.19,45,46,77
Tedeschi et al61 investigated the effects of a 3-month
therapy with tapentadol PR (ﬁnal mean dose 186.4
±56.0/day) in 25 diabetic patients with peripheral artery
disease at lower extremities; 24 (96%) patients had also
skin ulcers and 18 (72%) patients NP with intense par-
esthesia and allodynia (DN4≥4).
61 In comparison to base-
line, at month 3 of treatment pain NRS signiﬁcantly
declined from 7.9±1.2 to 2.8±2.3, DN4 from 4.0±1.2 to
1.2±1.5 and the number of NP patients from 18 to four
patients (72 vs 16%) (Mann–Whitney U test; P<0.01).61
During treatment with tapentadol, the quality of sleep and
the physical and mental components of SF-12 Health
Survey improved signiﬁcantly (P<0.01), suggesting the
potential efﬁcacy of tapentadol PR in this setting.61
Tapentadol for chemotherapy-induced neuropathy
In an open-label, 3-month, prospective study, Galiè et al
assessed the efﬁcacy of tapentadol in 31 patients with
moderate-to-severe NP from a CIPN that was unrespon-
sive to maximum doses of antineuropathic antidepressants,
and anticonvulsivants.62 CIPNs occurred after therapy
with taxane (45%) or platinum agents (32%) or their
combination for a solid tumor, mostly breast and digestive
cancers (36 and 26%).62 Tapentadol was titrated balancing
pain relief and adverse events (ﬁnal mean dose 200 mg/
day; personal communication). At baseline, all patients
were classiﬁed as having NP according to DN4 score.
62
From baseline to month 3 of treatment with tapentadol, the
average DN4 score declined from 6.36±1.4 to 4.18±0.73
(personal communication).62 Nerve conduction values
were unchanged from baseline to month 3 suggesting
that tapentadol relieved NP per se without affecting or
reversing peripheral nerve damage.62
Tapentadol in musculoskeletal
conditions with a neuropathic
component
According to the Global Burden of Disease reports 2010
and 2013, musculoskeletal conditions are the major causes
of disability with chronic low back pain (CLBP) being the
leading condition of disability, chronic neck pain (CNP)
ranking fourth and other musculoskeletal conditions and
osteoarthritis ranking tenth and thirteenth.12 CLBP and
CNP are classiﬁed as mixed pain syndromes that can
have nociceptive and/or NP components.78–88 Radicular
NP from nerve root involvement is a frequent and typical
NP component in CLBP and CNP. A NP symptom com-
ponent, however, has also been reported in osteoarthritis
and rheumatoid arthritis in the absence of overt nerve
lesions.27–32 In these painful conditions, NP has been
ascribed to pathological changes of articular nerves.28
Joint cartilage is poorly innervated in normal conditions
but may undergo neurovascular invasion in osteoarthritis;
in contrast, the highly innervated synovial membrane pre-
sents loss and plastic changes of nerve terminals.27–33
Furthermore, in functional magnetic resonance imaging,
CLBP patients with high PDQ scores presented with
decreased cortical activation in response to painful stimuli,
which suggests that CLBP may be associated to decreased
descending inhibitory modulation of pain.28–34,89,90
Although subtle pathological changes in peripheral and
central nervous system are hard to be conﬁrmed clinically,
they still may explain sensory and neurological abnormal-
ities including mechanical hyperalgesia and allodynia and
loss of proprioception and vibration sensitivity, which are
frequently found in osteoarthritis patients.27–32,34
The prevalence of a NP component in CLBP has been
investigated in a number of studies, and the results varied
signiﬁcantly according to the method used for diagnosing
neuropathic pain, ranging from 16.7% to 54.4%.78
Freynhagen et al78,79using their PDQ found that 37% of
8,000 screened CLBP patients had a predominant NP com-
ponent; when tested again by clinical, neurophysiological
and imaging methods, PDQ had a positive predictive accu-
racy of 80–85%.78,80 Using clinical judgement supported by
neurophysiological and neuroradiological ﬁndings, LANSS
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and PDQ, Liu et al found that mixed-to-deﬁnite NP can be
diagnosed in 57–72% of CNP patients.81 Patients with an
identiﬁed NP component have been reported to experience
more intense pain for a longer period of time than those
without, and to have a higher prevalence of psychiatric
comorbidities and disability.78–80 However, not all clinical
trials assessed the effects of tapentadol on the NP component
in the more severe forms of CLBP and CNP; NP may be
underdiagnosed and undertreated.
Tapentadol PR was evaluated in patients with severe
CLBP with a NP component (ie, PDQ ≥12).48 Patients
received open-label (study IIIb) tapentadol PR
(100–500 mg/day) for a 5-week titration and a subsequent
7-week maintenance period.48 Tapentadol PR treatment was
associated with signiﬁcant improvements in NP symptoms in
CLBP patients with a decreasing of both the numbers of pain
attacks and the duration of spontaneous pain (mean PDQ
decrease from baseline to study end 3.02±2.07; P< 0.0001);
interestingly, lower tapentadol doses were generally required
with increasing likelihood of NP. These promising results
have been corroborated by results obtained from an open-
label continuation arm of a second, randomized phase IIIb
study in patients with severe CLBP and a NP component (ie,
pain NRS ≥6 and PDQ ≥12). All patients were titrated to
tapentadol PR 300 mg/day over 3 weeks.82 A subpopulation
with pain intensity <4 continued receiving tapentadol PR
300 mg/day during an 8-week period.82 For the primary
study population, patients with ≥1-point decrease from base-
line and pain intensity ≥4 were randomized to tapentadol PR
500 mg/day or tapentadol PR 300 mg/day plus pregabalin
300 mg/day during a concurrent 8-week, double-blind com-
parative period (observed case analysis by paired t-test).82
The former subpopulation of patients with CLBP with a NP
component responded very well to tapentadol PR 300 mg/
day, with signiﬁcant improvements in NP-related symptoms
and quality of life (mean change from baseline to the end of
titration in the EuroQoL-5D health status index score was
0.36±0.370 and the mean change from baseline to the ﬁnal
evaluation was 0.39±0.389; one-sample paired t-test on
observed cases, P<0.0001 for both measures).82
Passavanti et al evaluated the effects of adding on
ultramicronized palmitoylethanolamide (PEA) to tapenta-
dol in a subset of patients with CLBP and a NP component
(ie, DN4≥4 and hyperalgesia and allodynia by pinprick test
and brush test).83 These authors used a mixed prospective-
retrospective design to compare the analgesic effects of
PEA 600 mg twice a day added to background therapy
with tapentadol in 35 patients in the prospective arm to
those of tapentadol alone in 20 patients of the retrospective
arm.83 Adding PEA synergistically augmented NP symp-
tom relief by tapentadol. DN4 scores at month 6 versus
baseline showed that tapentadol/PEA patients achieved
a signiﬁcantly greater NP symptom relief than tapentadol
patients.83 Both groups achieved signiﬁcant decrease the
NP component over baseline (generalized linear mixed
model and responder analyses, P<0.0001), but the NP
symptom reduction was signiﬁcantly greater in the tapen-
tadol/PEA than in the tapentadol group (ie, DN4 from 6.1
±0.14 to 3.2±0.13 and from 6.1±0.09 to 5.0±0.04, P<
0.0001).83
Baron et al carried out a 9-week, direct-comparison study
between tapentadol PR and oxycodone/naloxone PR in
patients with severe CLBP and a NP component (mean
daily maintenance doses: tapentadol 378.8±129.6 mg/day,
oxycodone/naloxone 75.3±24.3 mg/day).84 At baseline, 74
and 76% of patients had a positive PDQ score (ie, >18,
probable NP) in the tapentadol and in the oxycodone/nalox-
one group, respectively, and 25 and 21% had a PDQ unclear
score (ie, 12–18, mixed pain).71 Both tapentadol and the
oxycodone/naloxone were associated to signiﬁcant PDQ
decrease from baseline to treatment end; however, tapentadol
was associated with signiﬁcantly larger reductions of PDQ.84
In a retrospective analysis, Ueberall and Mueller-
Schwefe compared the analgesic effects of tapentadol ver-
sus oxycodone/naloxone in 261 CLBP patients randomly
selected from a larger patient dataset of the Germany Pain
Registry.85 At pretreatment baseline, a subgroup of
patients (109/261, 48%) presented probable NP (ie,
PDQ7 score ≥18). Tapentadol signiﬁcantly reduced aver-
age PDQ7 at week 12 compared with baseline as oxyco-
done/naloxone did (modiﬁed t-test on ITT and LOCF
population; P<0.001 for both treatments). From baseline
to the ﬁnal 12-week assessment, mean PDQ7 scores fell
from 17.7±3.4 to 12.7±5.2 in the tapentadol group and
from 18.2±3.7 to 12.4±6.3 in the oxycodone group
(P<0.001 for both treatments).85 At the same time, NP
patients decreased from 47 to 20% in the oxycodone/
naloxone group and from 37 to 22% in the tapentadol
group. There was no difference in the effectiveness on
NP between the two agents. The study has been criticized
for the arbitrary selection of subsets of patients and for
other relevant methodological biases.86,87
In an observational prospective study, tapentadol PR sig-
niﬁcantly (P<0.01) reduced NP intensity from baseline to
week in a subset of 54 CNP patients with moderate-to-severe
chronic pain and NP- (ie, DN4≥4) associated CNP.
88 The
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average DN4 score decreased from 4.1±2 at baseline to 1.9
±2.1 at the end of week 12 (Bonferroni corrected ANOVA and
t-test); in parallel, the percent of NP patients decreased from
70% (40/54) at baseline to 23% at study end (10/44).
Treatment with tapentadol was associated with improved
neck motion, and quality of sleep and life.88
Tapentadol in neuropathic cancer
pain
NP can be encountered in every stage of cancer, from the
preclinical stages of the disease until the end of life.91–94
Cancer NP can result from a direct invasion/compression of
the peripheral nervous systems, from an indirect paraneoplas-
tic involvement or light chain amyloidosis, or as
a consequence of therapeutic treatments (ie, surgery, radio-
therapy and chemotherapy).91–94
Coluzzi et al retrospectively analyzed 25 multiple mye-
loma patients treated with tapentadol (ﬁnal mean dose
213.6±94.1 mg/day) for moderate-to-intense pain.92 At
pretreatment assessment 18 patients (70%) presented NP,
as assessed with DN4.
92 Tapentadol was highly effective
on NP symptoms reducing mean DN4 score from 4.68
±2.43 at baseline to 0.41±0.91 at week 12 of treatment
and the numbers of patients with NP (Friedman test and
McNemar test; P<0.01, for both measures); at the same
time, all domains of SF-36 quality of life improved.92
Brunetti retrospectively analyzed the effects of tapenta-
dol on 36 patients treated for 1 month because of blood
malignancies.93 At baseline, 56% of patients (20/36) pre-
sented NP according to DN4. Tapentadol was slowly titrated
to a ﬁnal dose of 243.5±105.6 (personal communication). In
comparison to pretreatment, at month 1 of treatment the NP
patients decreased from 54 to 14%. Sleep quality improved
to “good” or “refreshing” from 20% to 95% of patients.93
Tapentadol in aging and Parkinson’s
disease
Chronic pain is common and may affect up to 60% of
elderly people aged 65 years or above.95 Pain is most
commonly a nociceptive musculoskeletal pain arising from
degenerative joint disease (ie, osteoarthritis).95 NP is com-
mon as well. In older adults, pain is often underdiagnosed
and undertreated. Potential gastrointestinal and cognitive
side effects of opioids are feared and limit their prescrip-
tions. However, in the older patients, inadequate pain man-
agement increases risk for cognitive and functional
impairment, depression, social withdrawal, and falls.95
Freo et al carried out a retrospective analysis on
96 patients with chronic musculoskeletal pain of
moderate-to-severe intensity (ie, duration >6 months,
pain NRS >4/10; low back and neck pain 89%, other
11%).96 In addition to standard pain questionnaires,
patients were assessed with a battery of cognitive tests
to assess and monitor potential cognitive side effects.96
The incidence of probable NP (ie, PDQ>18) declined
with age. At pretreatment, NP could be diagnosed in
42% (13/31) of patients of 65 years or younger, in 35%
(7/20) between 65 and 75 years, in 18% (6/34) between
75 and 85 years and 18% (2/11) in patients older than
85 years.96 After 6 months of treatment (mean daily
dose 267.6±122.1 mg/day), mean PDQ signiﬁcantly
declined in all age groups (Figure 2): from 16.9±4.9 to
7.2±3.3 below 65 years of age, from 14.6±7.3 to 7.2±3.2
between 65 and 75 years, from 11.8±5.3 to 6.5±3.2 and
from 10.0±62 to 6.2±2.9 in patients 75 to 85 or older
than 85 years of age, respectively (Bonferroni corrected
ANOVA and t test; P<0.01, for 6 months vs pretreat-
ment comparison in all age groups).96 Although neurop-
sychological performances tended to decline with age,
no further impairment was observed during treatment.96
Neurodegenerative diseases are also increasing in parallel
with life expectancy extension and population aging.23–29,95
Treatment guidelines and recommendations are focused on
core cognitive and motor symptoms and do not include
analgesics; as a consequence, pain is often underdiagnosed
and undertreated also in these conditions.95
In Parkinson’s disease (PD) pain is one of the most
frequent non-motor symptoms throughout the disease
course, sometimes preceding the clinical motor stage for
years.97 PD patients present prevalent nociceptive muscu-
loskeletal pain due to muscle stiffness and arthritis but also
pain with NP features.98 Typical PD pathological changes
are found early in the disease in brainstem noradrenergic
nuclei of locus coeruleus which project to the spinal dorsal
horns to modulate pain processing.82 Dopaminergic ther-
apeutic agents are only partially effective against this pain
condition, and nonsteroidal anti-inﬂammatory drugs are
considered only second-line treatment due to the asso-
ciated risk of adverse cardiovascular, gastrointestinal and
renal events, especially in the elderly.98 Moreover, physi-
cians are somehow reluctant to prescribe opioids to PD
patients since they can worsen motor and non-motor
symptoms, such as constipation, hallucinations, and day-
time sleepiness.42,99 Tapentadol has the potential to
enhance the noradrenergic tone in PD.39,40
Dovepress Freo et al
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In a retrospective study, Freo et al evaluated effects of
a 6-month treatment with tapentadol in 21 PD patients
(ﬁnal mean daily doses 206.3±102.7).100 Patients were
assessed for the intensity of pain with 0–10 pain NRS
and PDQ, for anxiety and depression with the Hospital
Anxiety and Depression Scale, for cognitive and motor
functions and for the quality of life with a set of neurop-
sychological tests.100 At baseline, pain was classiﬁed as
nociceptive, neuropathic and uncertain in eleven, three and
seven patients (52, 14 and 33%, respectively).100 NRS
pain intensity decreased signiﬁcantly over time (from
6.4±1.1 at baseline to 2.5±2.2 at month 6 of treatment,
Bonferroni corrected ANOVA and t test, P<0.0001), with
a ﬁnal ≥50% pain relief in ten patients (48%).100 From
baseline to month 6 of treatment PDQ decreased from
11.4±4.5 to 5.1±4.9 (P<0.0001) (Figure 3); symptoms of
anxiety and depression and the quality of life improved
signiﬁcantly. No decrement was observed in cognitive and
motor functions.100
Conclusion
NP in general remains a challenging condition, and “tradi-
tional” analgesic therapies are known to often be poorly
effective in this setting.
The pharmacological proﬁle of tapentadol, combining
synergistically MOR agonism and NRI in one molecule,
appears to be unique and it seems reasonable to propose for
tapentadol as the ﬁrst, and so far only – molecule of a new
class of central-acting analgesics, designated MOR-NRI.101
For tapentadol the experimental evidence that NRI is a key
mechanism that can be predominant in chronic neuropathic
pain, reinforces the concept that tapentadol is different to
classical opioids.102 This concept has been strengthened by
Raffa et al.101 and Pergolizzi et al.102 who stated that
recognition of subclasses of opioids is warranted scientiﬁ-
cally and beneﬁcial to healthcare providers, payers and
regulators; to date, some deﬁnitions have been proposed
such as 'atypical' analgesic or multigesic agent.101,102 To
date, tapentadol PR, at full doses (300–450 mg/day) proved
to be effective in the treatment of a challenging NP condi-
tion like DPN, and therefore may represent a suitable
a priori choice for these conditions
So far, however, only preliminary evidence supports the
use of this molecule in peripheral artery disease and PD. In any
case, the inclusion of the NRI component reduces the “opioid
load” andmay thusmitigate side effects associatedwith opioid
use – including those on cognitive function – in patients with
these painful conditions, who are often poly-medicated and do
require treatments with minimal potential of pharmacological
interactions. Although – with the exception of DPN – robust
randomized, placebo-controlled trials are missing for most
other types of chronic NP, evidence from animal models
32
28
24
20
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8
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0
<65 65-75 75-85 >85 years of age
Figure 2 Means (± SD) of painDetect questionnaire score (PDQ) at pretreatment (solid columns) and after 3-month (densely hatched columns) and 6-month (lightly
hatched columns) treatment with tapentadol for chronic musculoskeletal pain, across different age groups. **Different from baseline (P<0.01, 6-month PDQ vs pretreatment
PDQ, for all age group; 1-way ANOVA and t-test).
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suggests that NRI is a key mechanism and may even predomi-
nate over opioid actions in chronic (and especially neuropathic)
pain states, reinforcing that tapentadol is different to classical
opioids. Therefore, tapentadol PR should be a good choice for
a tentative treatment of neuropathic and mixed pain, but there
is still much room for further conclusive, high-quality clinical
studies with this drug in NP syndromes.
Key points
● NP remains a challenging condition, not least because
“traditional” analgesic therapies are often poorly
effective.
● Tapentadol is characterized by a peculiar dual
mechanism of action, namely the μ-opioid receptor
agonism and norepinephrine reuptake inhibition.
● This dual mode of action indicates its potential suitability
for a broad range of pain conditions, in particular when-
ever a NP component is present or cannot be excluded.
● Tapentadol is the ﬁrst central-acting analgesic that
has obtained a precise FDA recognition of speciﬁc
and documented efﬁcacy in the treatment of DPN.
● Tapentadol PR, at full doses (300–450mg/day) proved to
be effective in the treatment of a challenging condition,
such as DPN. However, so far only preliminary evidence
supports the use of this molecule for mixed pain in
peripheral artery disease and PD patients.
● In any case, the NRI component reduces the “opioid
load” and might thus mitigate common side effects
associated with opioid use – including those on cogni-
tive function.
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